BLACKSBURG, VA – Keraderm Corp., a company starting clinical trials of its technology to use phototherapy to treat nail and skin infections, has raised a $2.5 million first round from NewVa Capital Partners.

This is the final investment by NewVa Capital Partners is a private equity and venture capital fund managed by Third Security that has provided four other investments in early stage companies located or considering location in the NewVa region of southwest Virginia.

“This commitment by NewVa Capital Partners provides us with the capital and resources we need to complete our clinical trial, obtain approval for our device from the Food and Drug Administration and begin rolling out our product,” says Bill Cumbie, President and CEO of Keraderm.

Onychomycosis, a fungal infection of the nail, is a common disorder. In the United States during the past twelve months, 2.3 million prescriptions were written to treat this disease.

Current pharmaceutical therapies have limited efficacy and result in relatively high recurrence rates. In some cases, the drugs prescribed can have serious side effects. Keraderm’s device, which uses bursts of pulsed light to destroy the fungal infection, has demonstrated positive results in prior clinical trials.

The company is currently preparing for a pivotal trial designed to meet the requirements for approval from the U.S. Food and Drug Administration.

There are no approved non-invasive, non-drug based treatments for this disease.

Online: www.keraderm.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2009, TechJournal South. All rights reserved.